This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lazarous, D. F. Articles by Quyyumi, A. A. Search for Related Content PubMed PubMed Citation Articles by Lazarous, D. F. Articles by Quyyumi, A. A.

Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial

Daisy F. Lazarous, MD^* , Ellis F. Unger, MD^*, Stephen E. Epstein, MD, FACC^*, Annette Stine, RN^*, Josefino L. Arevalo, BSN, RN^*, Emily Y. Chew, MD and Arshed A. Quyyumi, MD, FACC^*

^* Cardiology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

View larger version (10K): [in a new window]   Figure 1 Area under the concentration-time curve or measure of total exposure to basic fibroblast growth factor demonstrated a dose-response relationship.

View larger version (14K): [in a new window]   Figure 2 Resting calf blood flow in all placebo and bFGF-treated patients at baseline and 1 month. The greatest improvement in calf blood flow occurred in a placebo patient. bFGF = basic fibroblast growth factor.

View larger version (23K): [in a new window]   Figure 3 Mean percent change in resting calf blood flow and vascular resistance in five patients who received one dose of 30 µg/kg of bFGF intraarterially, four patients who received two doses of 30 µg/kg of bFGF and all nine treated patients. Values represent mean ± SEM. The difference between time points (baseline, 1 and 6 months) is tested with analysis of variance. bFGF = basic fibroblast growth factor.